Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T14:27:07.717Z.
Calculation as of: 2026-10-06T14:27:07.717Z.
Quote observation: 2026-10-06T14:25:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d8f500f051b8c2f6d9df2326c38ce0bcf8edb39987555b97daf7c0f1a95d0fd4
EARNINGS YIELD
N/A
Market Cap
$116.57M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | $116.83M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.57M | N/A | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.54M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $114.79M | N/A | N/A | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | N/A | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $120.24M | N/A | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $112.52M | N/A | N/A | N/A | N/A |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $112.36M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $110.73M | N/A | 0.32% | 0.91% | 2.50% |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute